Record Revenue and Strong Growth
BrainsWay reported $11.4 million in revenue for Q4 2024, marking a 27% year-over-year increase. The full-year 2024 revenue was $41 million, a 29% increase from 2023.
Expansion of Deep TMS System
Shipped 75 Deep TMS systems in Q4 2024, a 25% increase over the same period last year. The total installed base reached 1,353 systems by year-end.
Positive Earnings and Financial Stability
Achieved positive quarterly net income for the fifth consecutive quarter and positive adjusted EBITDA for the sixth consecutive quarter. Ended the year with $69.4 million in cash and no debt.
Strategic Growth Initiatives
Plans for revenue growth of 20% to 24% in 2025, with operating income of 3% to 4% and adjusted EBITDA of 11% to 12%. Focus on expanding market presence and advancing next-generation Deep TMS 360 system.
Regulatory Approvals and Clinical Advances
FDA clearance for treating elderly patients with MDD, expansion of Deep TMS indications including OCD, and potential treatment for adolescent depression. Positive pilot data for treating alcohol addiction with Deep TMS.